Clarification on China agencies’ redundancy reduction effort
This article was originally published in The Gray Sheet
Executive Summary
Plan for China's Administration of Quality Supervision, Inspection and Quarantine and its State Food and Drug Administration to reduce redundancies between them by requiring only one test, one report, one fee and one factory inspection, applies to eight specific device types (1"The Gray Sheet" Sept. 22, 2008, p. 8). Other device types were not affected by the problem. The eight types include: X-ray systems, hemodialysis systems, extracorporeal circulation tubes for blood purification, hollow-fiber dialyzers, heart-lung machines, electrocardiographs, pacemakers and condoms
You may also be interested in...
Chinese Agencies’ Agreement Could Halve Approval Time For U.S. Devices
Chinese approval time for imported medical devices could be cut in half under an agreement to reduce redundancies between the country's Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) and its State Food and Drug Administration (SFDA)
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.